Table 1.
Clinical characteristics of the patients studied.
| Clinical characteristics | Training set | Testing set | ||||||
|---|---|---|---|---|---|---|---|---|
| Overall study population | NOAF | Without NOAF | P value | Overall study population | NOAF | Without NOAF | P value | |
| (n=807) | group (n=89) | group (n=718) | (n=282) | group (n=25) | group (n=257) | |||
| Age (years) | 65 (59-70) | 68 (62-72) | 64 (58-70) | 0.003 | 64 (57-68) | 69 (64-74) | 63 (57-68) | 0.001 |
| Sex (%) | <0.001 | 0.035 | ||||||
| Male | 589 (73.0) | 80 (89.9) | 509 (70.9) | 196 (69.5) | 22 (88.0) | 174 (67.7) | ||
| Female | 218 (27.0) | 9 (10.1) | 209 (29.1) | 86 (30.5) | 3 (12.0) | 83 (32.3) | ||
| Hypertension (%) | 138 (17.1) | 27 (30.3) | 111 (15.5) | <0.001 | 47 (16.7) | 5 (20.0) | 42 (16.3) | 0.582 |
| Diabetes (%) | 62 (7.7) | 12 (13.5) | 50 (7.0) | 0.029 | 26 (9.2) | 3 (12.0) | 23 (8.9) | 0.714 |
| Coronary heart disease (%) | 30 (3.7) | 8 (9.0) | 22 (3.1) | 0.012 | 14 (5.0) | 2 (8.0) | 12 (4.7) | 0.358 |
| Smoking history (%) | 289 (35.8) | 53 (59.6) | 236 (32.9) | <0.001 | 102 (36.2) | 14 (56.0) | 88 (34.2) | 0.031 |
| Classification (%) | <0.001 | 0.024 | ||||||
| CPC | 312 (38.7) | 54 (60.7) | 258 (35.9) | 110 (39.0) | 15 (60.0) | 95 (37.0) | ||
| PPC | 495 (61.3) | 35 (39.3) | 460 (64.1) | 172 (61.0) | 10 (40.0) | 162 (63.0) | ||
| PE | 115 (14.3) | 22 (24.7) | 93 (13.0) | 0.003 | 43 (15.2) | 8 (32.0) | 35 (13.6) | 0.035 |
| Location (%) | 0.471 | 0.816 | ||||||
| Left | 352 (43.6) | 42 (47.2) | 310 (43.2) | 119 (42.2) | 10 (40.0) | 109 (42.4) | ||
| Right | 455 (56.4) | 47 (52.8) | 408 (56.8) | 163 (57.8) | 15 (60.0) | 148 (57.6) | ||
| Histology (%) | 0.514 | 1.000 | ||||||
| NSCLC | 638 (79.1) | 68 (76.4) | 570 (79.4) | 239 (84.8) | 21 (84.0) | 218 (84.8) | ||
| SCLC | 169 (20.9) | 21 (23.6) | 148 (20.6) | 43 (15.2) | 4 (16.0) | 39 (15.2) | ||
| Therapy | 0.720 | 0.320 | ||||||
| Chemotherapy regimens | 730 (90.5) | 81 (91.0) | 649 (90.4) | 223 (79.1) | 22 (88.0) | 201 (78.2) | ||
| Paclitaxel | 72 (8.9) | 6 (6.7) | 66 (9.2) | 53 (18.8) | 7 (28.0) | 46 (17.9) | ||
| Others | 658 (81.5) | 75 (84.3) | 583 (81.2) | 170 (60.3) | 15 (60.0) | 155 (60.3) | ||
| Non-chemotherapy | 77 (9.5) | 8 (9.0) | 69 (9.6) | 59 (20.9) | 3 (12.0) | 56 (21.8) | ||
| CRP (mg/L) | 3.53 (0.96-13.53) | 9.81 (2.51-32.67) | 3.21 (0.90-12.07) | <0.001 | 5.11 (1.53-19.68) | 11.98 (4.20-30.27) | 4.91 (1.45-19.68) | 0.030 |
| Potassium (mmol/L) | 4.1 (3.9-4.3) | 4.1 (3.9-4.4) | 4.1 (3.9-4.3) | 0.451 | 4.0 (3.9-4.3) | 4.2 (3.9-4.4) | 4.0 (3.8-4.2) | 0.109 |
| TTE | ||||||||
| LAD (mm) | 35 (32-37) | 35 (33-39) | 35 (32-37) | 0.042 | 36 (34-38) | 36 (34-40) | 36 (34-38) | 0.185 |
| LVESD (mm) | 28 (26-30) | 29 (27-30) | 28 (26-30) | 0.604 | 29 (27-32) | 30 (28-33) | 29 (27-32) | 0.091 |
| LVEDD (mm) | 47 (44-49) | 47 (45-49) | 47 (44-49) | 0.908 | 47 (44-50) | 48 (46-48) | 47 (44-50) | 0.978 |
| LVEF (%) | 64 (62-65) | 64 (62-65) | 64 (62-65) | 0.164 | 65 (63-67) | 64 (61-65) | 65 (64-67) | 0.001 |
Data are presented as median (interquartile range) or n (%). NOAF, new-onset atrial fibrillation; CPC, centric pulmonary carcinoma; PPC, peripheral pulmonary carcinoma; PE, pericardial effusion; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; CRP, c-reactive protein; TTE, transthoracic echocardiography; LAD, left atrial diameter; LVESD, left ventricular end diastolic diameter; LVEDD, left ventricular end diastolic diameter;LVEF, left ventricular ejection fraction.